David L. Fitzgerald

Array ( [id] => 4018897 [patent_doc_number] => 05882640 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 1999-03-16 [patent_title] => 'Treatment of hyperallergenic response with oral interferon' [patent_app_type] => 1 [patent_app_number] => 8/475753 [patent_app_country] => US [patent_app_date] => 1995-06-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7005 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 126 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/05/882/05882640.pdf [firstpage_image] =>[orig_patent_app_number] => 475753 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 3831430 [patent_doc_number] => 05846526 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 1998-12-08 [patent_title] => 'Treatment of autoimmune disorders with oral interferon' [patent_app_type] => 1 [patent_app_number] => 8/476621 [patent_app_country] => US [patent_app_date] => 1995-06-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7012 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 96 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/05/846/05846526.pdf [firstpage_image] =>[orig_patent_app_number] => 476621 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 3695627 [patent_doc_number] => 05679772 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 1997-10-21 [patent_title] => 'Mammalian retinol-binding protein receptors' [patent_app_type] => 1 [patent_app_number] => 8/488305 [patent_app_country] => US [patent_app_date] => 1995-06-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 19 [patent_no_of_words] => 5908 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 43 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/05/679/05679772.pdf [firstpage_image] =>[orig_patent_app_number] => 488305 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 4232659 [patent_doc_number] => 06074840 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 2000-06-13 [patent_title] => 'Recombinant production of latent TGF-beta binding protein-3 (LTBP-3)' [patent_app_type] => 1 [patent_app_number] => 8/479722 [patent_app_country] => US [patent_app_date] => 1995-06-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 17 [patent_no_of_words] => 42001 [patent_no_of_claims] => 43 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 25 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/074/06074840.pdf [firstpage_image] =>[orig_patent_app_number] => 479722 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 4098365 [patent_doc_number] => 06051217 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 2000-04-18 [patent_title] => 'Therapeutic uses of interleukin-3 (IL-3) multiple mutation polypeptides' [patent_app_type] => 1 [patent_app_number] => 8/470081 [patent_app_country] => US [patent_app_date] => 1995-06-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 25 [patent_figures_cnt] => 25 [patent_no_of_words] => 115966 [patent_no_of_claims] => 132 [patent_no_of_ind_claims] => 36 [patent_words_short_claim] => 925 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/051/06051217.pdf [firstpage_image] =>[orig_patent_app_number] => 470081 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 3937945 [patent_doc_number] => 05997857 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 1999-12-07 [patent_title] => 'Co-administration of interleukin-3 mutants with colony stimulating factors' [patent_app_type] => 1 [patent_app_number] => 8/470509 [patent_app_country] => US [patent_app_date] => 1995-06-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 40343 [patent_no_of_claims] => 50 [patent_no_of_ind_claims] => 18 [patent_words_short_claim] => 527 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/05/997/05997857.pdf [firstpage_image] =>[orig_patent_app_number] => 470509 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 4182306 [patent_doc_number] => 06093395 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 2000-07-25 [patent_title] => 'Co-administration of interleukin-3 mutant polypeptides with CSF\'s for multi-lineage hematopoietic cell production' [patent_app_type] => 1 [patent_app_number] => 8/469712 [patent_app_country] => US [patent_app_date] => 1995-06-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 5 [patent_no_of_words] => 56517 [patent_no_of_claims] => 56 [patent_no_of_ind_claims] => 24 [patent_words_short_claim] => 249 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/093/06093395.pdf [firstpage_image] =>[orig_patent_app_number] => 469712 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 4002542 [patent_doc_number] => 05858969 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 1999-01-12 [patent_title] => 'Therapeutic methods employing sialylated glycoforms of soluble complement receptor 1 (SCR 1)' [patent_app_type] => 1 [patent_app_number] => 8/470867 [patent_app_country] => US [patent_app_date] => 1995-06-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 12 [patent_no_of_words] => 14192 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 12 [patent_words_short_claim] => 76 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/05/858/05858969.pdf [firstpage_image] =>[orig_patent_app_number] => 470867 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 4134495 [patent_doc_number] => 06060047 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 2000-05-09 [patent_title] => 'Co-administration of interleukin-3 mutant polypeptides with CSF\'s for multi-lineage hematopoietic cell production' [patent_app_type] => 1 [patent_app_number] => 8/471045 [patent_app_country] => US [patent_app_date] => 1995-06-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 5 [patent_no_of_words] => 56534 [patent_no_of_claims] => 31 [patent_no_of_ind_claims] => 13 [patent_words_short_claim] => 35 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/060/06060047.pdf [firstpage_image] =>[orig_patent_app_number] => 471045 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 3551483 [patent_doc_number] => 05543141 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 1996-08-06 [patent_title] => 'Therapeutic methods using interleukin-3 (IL-3) human/murine hybrid polypeptides' [patent_app_type] => 1 [patent_app_number] => 8/466647 [patent_app_country] => US [patent_app_date] => 1995-06-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 20 [patent_figures_cnt] => 20 [patent_no_of_words] => 27583 [patent_no_of_claims] => 1 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 105 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/05/543/05543141.pdf [firstpage_image] =>[orig_patent_app_number] => 466647 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 4102870 [patent_doc_number] => 06022535 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 2000-02-08 [patent_title] => 'Treatment of hematopoietic disorders with fusion proteins comprising multiply mutated interleukin-3 (IL-3) polypeptides and second growth factors' [patent_app_type] => 1 [patent_app_number] => 8/469318 [patent_app_country] => US [patent_app_date] => 1995-06-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 7 [patent_no_of_words] => 106639 [patent_no_of_claims] => 62 [patent_no_of_ind_claims] => 31 [patent_words_short_claim] => 92 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/022/06022535.pdf [firstpage_image] =>[orig_patent_app_number] => 469318 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 4140636 [patent_doc_number] => 06030812 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 2000-02-29 [patent_title] => 'Fusion proteins comprising multiply mutated interleukin-3 (IL-3) polypeptides and second growth factors' [patent_app_type] => 1 [patent_app_number] => 8/468609 [patent_app_country] => US [patent_app_date] => 1995-06-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 7 [patent_no_of_words] => 106732 [patent_no_of_claims] => 66 [patent_no_of_ind_claims] => 13 [patent_words_short_claim] => 87 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/030/06030812.pdf [firstpage_image] =>[orig_patent_app_number] => 468609 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 4406122 [patent_doc_number] => 06238889 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 2001-05-29 [patent_title] => 'Molecular cloning and expression of the Pro8 isoform of human IL-3' [patent_app_type] => 1 [patent_app_number] => 8/470369 [patent_app_country] => US [patent_app_date] => 1995-06-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 32 [patent_figures_cnt] => 35 [patent_no_of_words] => 18185 [patent_no_of_claims] => 34 [patent_no_of_ind_claims] => 8 [patent_words_short_claim] => 22 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/238/06238889.pdf [firstpage_image] =>[orig_patent_app_number] => 470369 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 3507019 [patent_doc_number] => 05587162 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 1996-12-24 [patent_title] => 'Treatment of allograft rejection with IL-2 receptor-specific cytotoxins' [patent_app_type] => 1 [patent_app_number] => 8/471841 [patent_app_country] => US [patent_app_date] => 1995-06-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 3934 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 68 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/05/587/05587162.pdf [firstpage_image] =>[orig_patent_app_number] => 471841 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 3993180 [patent_doc_number] => 05858347 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 1999-01-12 [patent_title] => 'Therapeutic methods using fusion proteins between interleukin-3 (IL-3) variants and other hematopoietic factors' [patent_app_type] => 1 [patent_app_number] => 8/470775 [patent_app_country] => US [patent_app_date] => 1995-06-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 41017 [patent_no_of_claims] => 53 [patent_no_of_ind_claims] => 22 [patent_words_short_claim] => 89 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/05/858/05858347.pdf [firstpage_image] =>[orig_patent_app_number] => 470775 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 4081206 [patent_doc_number] => 06017523 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 2000-01-25 [patent_title] => 'Therapeutic methods employing mutant human interleukin-3 (IL-3) polypeptides' [patent_app_type] => 1 [patent_app_number] => 8/471039 [patent_app_country] => US [patent_app_date] => 1995-06-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 16 [patent_no_of_words] => 110117 [patent_no_of_claims] => 90 [patent_no_of_ind_claims] => 24 [patent_words_short_claim] => 900 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/017/06017523.pdf [firstpage_image] =>[orig_patent_app_number] => 471039 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 3772974 [patent_doc_number] => 05817486 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 1998-10-06 [patent_title] => 'Recombinant human interleukin-3 (IL-3) multiple mutation polypeptides' [patent_app_type] => 1 [patent_app_number] => 8/469319 [patent_app_country] => US [patent_app_date] => 1995-06-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 25 [patent_figures_cnt] => 25 [patent_no_of_words] => 97509 [patent_no_of_claims] => 130 [patent_no_of_ind_claims] => 22 [patent_words_short_claim] => 18 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/05/817/05817486.pdf [firstpage_image] =>[orig_patent_app_number] => 469319 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 3525467 [patent_doc_number] => 05541103 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 1996-07-30 [patent_title] => 'CD34+ peripheral blood progenitor cells obtained by ex vivo expansion' [patent_app_type] => 1 [patent_app_number] => 8/467555 [patent_app_country] => US [patent_app_date] => 1995-06-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 5 [patent_no_of_words] => 3668 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 68 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/05/541/05541103.pdf [firstpage_image] =>[orig_patent_app_number] => 467555 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 3697099 [patent_doc_number] => 05674494 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 1997-10-07 [patent_title] => 'Treating non-malignant disease states with IL-2 receptor-specific substances' [patent_app_type] => 1 [patent_app_number] => 8/485554 [patent_app_country] => US [patent_app_date] => 1995-06-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 3930 [patent_no_of_claims] => 32 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 64 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/05/674/05674494.pdf [firstpage_image] =>[orig_patent_app_number] => 485554 [rel_patent_id] =>[rel_patent_doc_number] =>)